Percutaneous Transhepatic Intrahepatic Portosystemic Shunt for Treatment of Portal Vein Occlusion With Symptomatic Portal Hypertension After Splenectomy

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02505152

Enrollment

Registered

2015-07-22

Start date

2010-10-31

Completion date

Unknown

Last updated

2015-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension, Portal, Portal Vein, Cavernous Transformation Of

Keywords

Hypertension, Portal, Portal Vein, Cavernous Transformation Of, Portosystemic shunt, Radiology, Interventional

Brief summary

To evaluate the values of percutaneous transhepatic intrahepatic portosystemic shunt for treatment of portal vein occlusion with symptomatic portal hypertension after splenectomy.

Interventions

PROCEDUREPercutaneous transhepatic intrahepatic portosystemic shunt

Under fluoroscopic guidance, portal vein(PV) was punctured with a 22-gauge Chiba needle. A 0.018-inch guidewire was advanced through the needle into PV lumen. The needle was exchanged and a 7-French sheath inserted over the wire. Then retrohepatic inferior vena cava(RIVC) or hepatic vein(HV) was punctured with a 20-gauge, 30-cm Chiba needle through sheath. Another 0.018-inch guidewire was advanced through the needle into right internal jugular vein and then snared out of body. A 0.035-inch, 260-cm stiff shaft wire was then introduced through the transjugular sheath and manipulated into main portal vein(MPV) and then into superior mesenteric vein(SMV). Afterward the PTIPS procedure was completed in the standard transjugular fashion.

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* All patients with portal hypertension who have the history of splenectomy and have enough image information to confirm occlusion of portal vein

Exclusion criteria

* Patients with known severe dysfunction of heart, lung, brain, kidney and other vital organs

Design outcomes

Primary

Measure	Time frame	Description
No gastrointestinal rebleeding in 1 month after interventions	1 month	No gastrointestinal rebleeding in 1 month after interventions
Ascites disappear in 1 month after interventions	1 month	Ascites disappear in 1 month after interventions

Secondary

Measure	Time frame	Description
Whether the shunt is patent after interventions in 6 months	6 months	Patent shunt in 6 months after interventions proved by US or CT

Countries

China

Contacts

Primary ContactZaibo Jiang, MD.

jiangzaibo@aliyun.com+86 020 85252066

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026